Fred Eshelman
Chairman chez ARAVIVE, INC.
Fortune : 4 M $ au 31/03/2024
Profil
Fredric N.
Eshelman is the founder of PPD, Inc. (founded in 1985) and Pharmaceutical Product Development LLC (founded in 1985).
He is also the founder of Incyclix Bio LLC (founded in 2020) and Eshelman Ventures LLC.
Currently, Dr. Eshelman is the Chief Executive Officer & Director at Innocrin Pharmaceuticals Holdings LLC, Chief Executive Officer & Director at Innocrin Pharmaceuticals, Inc., Chairman at Cellective BioTherapy, Inc., Executive Chairman at Aravive, Inc. (since 2022), and Director at Dignify Therapeutics LLC, Aton Pharma, Inc., Aero MD, North Carolina School of Science & Mathematics, and the University of North Carolina System.
Formerly, he served as the Executive Chairman at The Medicines Co. (2017-2020), Chairman at Furiex Pharmaceuticals, Inc. (2011-2014), Chairman at Eyenovia, Inc. (2018-2022), and Director at XORI Corp., Neoantigenics, Inc., Jumo Health, Inc., The North Carolina Biotechnology Center, Glaxo, Inc. (1989-1990), Bausch Health Cos., Inc. (2015-2018), G1 Therapeutics, Inc. (2015-2021), Meryx, Inc., Asepticys LLC, Amplitude Healthcare Acquisition Corp., Kinnate Biopharma, Inc., The University of North Carolina at Wilmington, North Carolina General Assembly (North Carolina), Accelerator Services Corp, Boehringer Mannheim Pharmaceuticals Corp., and Harvard Business School.
Dr. Eshelman holds a doctorate degree from the University of Cincinnati (Ohio) and an undergraduate degree from The University of North Carolina at Chapel Hill.
Dr. Eshelman is also the founder of Eshelman Ventures LLC.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
G1 THERAPEUTICS, INC.
1,05% | 18/11/2022 | 550 000 ( 1,05% ) | 2 M $ | 31/03/2024 |
EYENOVIA, INC.
2,73% | 10/11/2022 | 1 292 787 ( 2,73% ) | 1 M $ | 31/03/2024 |
ARAVIVE, INC.
-.--% | 03/08/2023 | 0 ( -.--% ) | - $ | 31/12/2023 |
Postes actifs de Fred Eshelman
Sociétés | Poste | Début |
---|---|---|
ARAVIVE, INC. | Chairman | 08/04/2020 |
Aero MD | Director/Board Member | - |
University of North Carolina System | Director/Board Member | - |
Innocrin Pharmaceuticals Holdings LLC
Innocrin Pharmaceuticals Holdings LLC Medical SpecialtiesHealth Technology Innocrin Pharmaceuticals Holdings LLC discovers and develops oral inhibitors for the treatment of Castration-Resistant Prostate Cancer (CRPC). The company is headquartered in Durham, NC. | Chief Executive Officer | - |
Dignify Therapeutics LLC
Dignify Therapeutics LLC Pharmaceuticals: MajorHealth Technology Dignify Therapeutics LLC offers pharmaceutical services. It provides bladder and bowel for people who have spinal cord injury. The company was founded by Edward C. Burgard, Karl B. Thor, Lesley Marson, Venkateswarlu Karicheti, Daniel J. Ricca, Florenta Aura Kullmann, Ebrahim Versi, Benny L. Ward, Tatyana Touzova and Mary Katofiasc and is headquartered in Research Triangle Park, NC. | Director/Board Member | - |
Cellective BioTherapy, Inc.
Cellective BioTherapy, Inc. Pharmaceuticals: MajorHealth Technology Cellective BioTherapy, Inc. engages in the research and development of novel cellular and monoclonal antibody-based platforms for treating cancers, autoimmunity, and immunodeficiency. Its proprietary pipeline and technology platform focuses on the unique aspects of B cell biology that are involved in regulating a variety of autoimmune diseases and inflammatory immune responses. The company was founded by Thomas F. Tedder in 2015 and is headquartered in Durham, NC. | Chairman | - |
North Carolina School of Science & Mathematics | Director/Board Member | - |
Innocrin Pharmaceuticals, Inc.
Innocrin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Innocrin Pharmaceuticals, Inc. develops oral inhibitors for the treatment of castration-resistant prostate cancer. It develops small molecule CYP17 lyase-selective inhibitors to treat resistant hormonally-dependent breast and prostate cancers. The firm’s product under pipeline is VT-464, a dual mechanism lyase-selective CYP17 inhibitor and androgen receptor (AR) antagonist that disrupts the validated biochemical pathways required for prostate cancer growth androgen biosynthesis and AR transcriptional signaling. The company was founded in 2004 and is headquartered in Durham, NC. | Chief Executive Officer | - |
Eshelman Ventures LLC
Eshelman Ventures LLC Investment ManagersFinance Eshelman Ventures LLC (Eshelman Ventures) is a venture capital firm founded in 2014 by Fredric N. Eshelman. The firm is headquartered in Wilmington, North Carolina. | Founder | - |
░░░░ ░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Anciens postes connus de Fred Eshelman
Sociétés | Poste | Fin |
---|---|---|
░░░░░░░░░ ░░░░ | ░░░░░░░░ | ░░░░░░░░░░ |
░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░ ░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░░ ░░░░░░░░░░░░░░░ ░░░ | ░░░░░░░░ | ░░░░░░░░░░ |
Formation de Fred Eshelman
University of Cincinnati (Ohio) | Doctorate Degree |
The University of North Carolina at Chapel Hill | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 4 |
---|---|
BAUSCH HEALTH COMPANIES INC. | Health Technology |
G1 THERAPEUTICS, INC. | Health Technology |
EYENOVIA, INC. | Health Technology |
ARAVIVE, INC. | Health Technology |
Entreprise privées | 24 |
---|---|
Pharmaceutical Product Development LLC
Pharmaceutical Product Development LLC Miscellaneous Commercial ServicesCommercial Services Pharmaceutical Product Development LLC engages in the operation of a global contract research organization, which provides drug development, laboratory and lifecycle management services. It offers adaptive trial design, bio analytical lab, bio similar development, biostatistics, GMP lab, clinical supplies, trial monitoring, CMC regulatory, data management, dental pain clinic, real-world outcomes, site intelligence and activation, central lab, global regulatory affairs, IRT systems, late stage research, medical communications, device and diagnostics, medical writing, nonclinical development and regulatory consulting and intelligence, regulatory development, innovation and vaccine sciences. The company was founded by Fredric N. Eshelman in 1985 and is headquartered in Wilmington, NC. | Commercial Services |
The Medicines Co.
The Medicines Co. Pharmaceuticals: MajorHealth Technology The Medicines Co. is a biopharmaceutical company, which focuses on saving lives, alleviating suffering and contributing to the economics of healthcare by focusing on acute and intensive care hospitals worldwide. The firm markets its brands Angiomax, Cleviprex, injectable emulsion, Ionsys, Kengreal, Minocin for injection, and Orbactiv. The company was founded by Clive A. Meanwell, Helmut Giersiefen, John W. Villiger and T. Scott Johnson on July 31, 1996 and is headquartered in Parsippany, NJ. | Health Technology |
XORI Corp.
XORI Corp. BiotechnologyHealth Technology XORI Corp. provides health technology services. It develops technology for the rapid discovery and development of monoclonal antibodies (MAbs). The firm validates the technology on a variety of targets and develops superior products for cancer therapy, immune disorders, and infectious diseases. The company was founded by Nancy Maizels in 2009 and is headquartered in Seattle, WA. | Health Technology |
Furiex Pharmaceuticals, Inc.
Furiex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Furiex Pharmaceuticals, Inc. operates as a drug development collaboration company that uses innovative clinical development design to accelerate and increase value of drug development programs by advancing them through the drug discovery and development process in a cost-efficient manner. Its drug development programs are designed and driven by a core team with extensive drug development experience. Furiex Pharmaceuticals was founded in 1998 and is headquartered in Morrisville, NC. | Health Technology |
Neoantigenics, Inc.
Neoantigenics, Inc. Medical SpecialtiesHealth Technology Neoantigenics, Inc. developes therapeutic plus diagnostic products. The firm focuses on developing oncology theranostics products, founded on the novel science around oocyte (egg)-associated cancer proteins. The company was founded Brian A. Pollok, John C. Herr and Edward J. Leary in July 2012 and is headquartered in Charlottesville, VA. | Health Technology |
Jumo Health, Inc.
Jumo Health, Inc. Medical/Nursing ServicesHealth Services Jumo Health, Inc. operates as a children’s health education company which produces health content for children and families. The firms products allow children, families, and caregivers to learn and better manage their condition through podcasts, videos, games, and more. The company was founded by Kim Chilman-Blair and Kate Hersov in 2009 and is headquartered in New York, NY. | Health Services |
Dignify Therapeutics LLC
Dignify Therapeutics LLC Pharmaceuticals: MajorHealth Technology Dignify Therapeutics LLC offers pharmaceutical services. It provides bladder and bowel for people who have spinal cord injury. The company was founded by Edward C. Burgard, Karl B. Thor, Lesley Marson, Venkateswarlu Karicheti, Daniel J. Ricca, Florenta Aura Kullmann, Ebrahim Versi, Benny L. Ward, Tatyana Touzova and Mary Katofiasc and is headquartered in Research Triangle Park, NC. | Health Technology |
Innocrin Pharmaceuticals Holdings LLC
Innocrin Pharmaceuticals Holdings LLC Medical SpecialtiesHealth Technology Innocrin Pharmaceuticals Holdings LLC discovers and develops oral inhibitors for the treatment of Castration-Resistant Prostate Cancer (CRPC). The company is headquartered in Durham, NC. | Health Technology |
Aton Pharma, Inc.
Aton Pharma, Inc. Pharmaceuticals: MajorHealth Technology Aton Pharma, Inc. develops therapeutics for cancer and other diseases. Its products include Edecrin, Sodium Edecrin, Cuprimine, Demser and Syprine. The company was founded by Michael G. Wells in 2001 and is headquartered in Lawrenceville, NJ. | Health Technology |
The North Carolina Biotechnology Center
The North Carolina Biotechnology Center Internet Software/ServicesTechnology Services The North Carolina Biotechnology Center provides research and education grants. Its services include financing, technology assessment, business planning, and marketing strategies implementation. The company was founded in 1984 and is headquartered in Research Triangle Park, NC. | Technology Services |
North Carolina General Assembly (North Carolina) | Government |
Accelerator Services Corp
Accelerator Services Corp Investment ManagersFinance Accelerator Services Corp (Accelerator Services) is a venture capital firm founded in 2003 by Carl Weissman and Rodney F. Burgar. The firm is headquartered in Seattle, Washington. | Finance |
Boehringer Mannheim Pharmaceuticals Corp. | |
Glaxo, Inc. | |
Meryx, Inc.
Meryx, Inc. Pharmaceuticals: MajorHealth Technology Meryx, Inc. operates as an immune-oncology company. It focuses on developing drugs that inhibit tumor growth and initiate anti-tumor immunity in a range of cancer, such as leukemia, lung cancer, and melanoma. The company was founded by Doug Graham, Shelley Earp, and Stephen Frye in 2007 and is headquartered in Chapel Hill, NC. | Health Technology |
Eshelman Ventures LLC
Eshelman Ventures LLC Investment ManagersFinance Eshelman Ventures LLC (Eshelman Ventures) is a venture capital firm founded in 2014 by Fredric N. Eshelman. The firm is headquartered in Wilmington, North Carolina. | Finance |
Cellective BioTherapy, Inc.
Cellective BioTherapy, Inc. Pharmaceuticals: MajorHealth Technology Cellective BioTherapy, Inc. engages in the research and development of novel cellular and monoclonal antibody-based platforms for treating cancers, autoimmunity, and immunodeficiency. Its proprietary pipeline and technology platform focuses on the unique aspects of B cell biology that are involved in regulating a variety of autoimmune diseases and inflammatory immune responses. The company was founded by Thomas F. Tedder in 2015 and is headquartered in Durham, NC. | Health Technology |
Aero MD | |
Asepticys LLC
Asepticys LLC Financial ConglomeratesFinance Asepticys LLC is a development stage company focused on chemically-unique medical disinfection solutions. The company was founded in 2015 and is headquartered in New Orleans, LA. | Finance |
PPD, Inc.
PPD, Inc. Miscellaneous Commercial ServicesCommercial Services PPD, Inc. engages in the provision of drug development services to the biopharmaceutical industry, focuses on helping customers bring their new medicines to patients around the world. It operates through the Clinical Development Services and Laboratory Services segments. The Clinical Development Services segment focuses in early development/Phase I, patient recruitment and enrollment, investigator site management, Phase II-IV clinical trial management, medical communications and various peri- and post-approval services. The Laboratory Services segment comprises of bioanalytical, vaccine sciences, GMP, central lab and biomarker testing. The company was founded by Fred Eshelma in 1985 and is headquartered in Wilmington, NC. | Commercial Services |
Amplitude Healthcare Acquisition Corp.
Amplitude Healthcare Acquisition Corp. Financial ConglomeratesFinance Amplitude Healthcare Acquisition Corp. operates as a blank check company. It aims to acquire one or more businesses and assets through a merger, share purchase and reorganization. The company was founded on August 13, 2019 and is headquartered in New York, NY. | Finance |
Kinnate Biopharma, Inc.
Kinnate Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Kinnate Biopharma, Inc. operates as a biopharmaceutical company engaged in the research and development of Kinnate Discovery Engine that targets genomic drivers of cancer. The company was founded by Stephen W. Kaldor and Eric A. Murphy in January 2018 and is headquartered in San Diego, CA. | Health Technology |
Incyclix Bio LLC
Incyclix Bio LLC Pharmaceuticals: MajorHealth Technology Incyclix Bio, Inc., formerly known as Arc Therapeutics, is a pharmaceutical company that focuses on developing small molecule inhibitors of cyclin-dependent kinases (CDKs) to treat advanced and resistant cancers. The company is based in Durham, NC. The company's team has unique insights into the biology and structure of CDKs, which will facilitate the rapid discovery and development of a novel, potent, and selective Cdk2 inhibitor. Incyclix Bio was founded by industry experts with robust drug design, discovery, and development experience, including Patrick Roberts, John Bisi, Fredric N. Eshelman, and Jay C. Strum. Patrick Roberts has been the CEO since incorporation. | Health Technology |
Innocrin Pharmaceuticals, Inc.
Innocrin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Innocrin Pharmaceuticals, Inc. develops oral inhibitors for the treatment of castration-resistant prostate cancer. It develops small molecule CYP17 lyase-selective inhibitors to treat resistant hormonally-dependent breast and prostate cancers. The firm’s product under pipeline is VT-464, a dual mechanism lyase-selective CYP17 inhibitor and androgen receptor (AR) antagonist that disrupts the validated biochemical pathways required for prostate cancer growth androgen biosynthesis and AR transcriptional signaling. The company was founded in 2004 and is headquartered in Durham, NC. | Health Technology |